Clinical Trial Update: Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluating CX-4945 in combination with gemcitabine and cisplatin for frontline treatment of cholangiocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• CX-4945 (silmitasertib)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Senhwa Biosciences, Inc. | Conditions: Cholangiocarcinoma | Phase 1, Phase 2 | Status: COMPLETED